| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
Solid Biosciences Inc.
13D/A
SLDB · 83422E105
|
8.8% |
3/10/2026
Event 3/6/2026
|
||||
| BCLS SB Investco, LP | 0% | |||||
| Bain Capital Life Sciences Fund II, L.P. | 0.3% | |||||
| BCLS II Investco, LP | 8.8% | |||||
| BCIP Life Sciences Associates, LP | 0.1% | |||||
| BCLS II Equity Opportunities, LP | 1.0% | |||||
| Bain Capital Life Sciences Opportunities IV, L.P. | 5.4% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.